Answers in one place.

No. Our technology analyses and matches, but a molecular tumour board of licensed clinicians authors and signs every decision.

Often not. Many Signature tests use a simple blood draw (liquid biopsy). If you already have a tumour block, Signature STt O uses that. If you have prior results, Decipher may avoid new testing altogether.

A liquid biopsy may be less informative in that case, and a "not detected" result cannot rule out disease. Your team may recommend tissue testing (STt O) instead. We always state this limitation openly.

Sentinel monitors during active treatment (is it working, is resistance emerging). Clear monitors after curative-intent treatment (is anything left, is it returning).

Yes. Every plan surfaces clinically-equivalent biosimilars, Patient Assistance Programmes, and government schemes, and your navigator helps you access them.

Yes. Reports come with a plain-language summary in your regional language, and resources and videos are translated.

Request one from any page or through your navigator. Second opinions and molecular tumour board discussions are provided by KPCIRC on a paid basis.

Yes. Data is encrypted and access-controlled, handled under India's DPDPA 2023, and used for research only with your separate, explicit consent.

No. Histocommon AI, Digital Twin Oncology, Dendritic Cell Vaccine Screening, In Vivo Avatars, the Spatial Immune Atlas, and the Federated Evidence Network are research and development — not clinical services.